|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
Acquired by a larger medical device company in 2018
|
|
gptkbp:ceo
|
gptkb:Dr._John_M._Mc_Donald
|
|
gptkbp:employees
|
Approximately 50-100
|
|
gptkbp:focus
|
Innovative solutions for vascular disease
|
|
gptkbp:founded
|
gptkb:2011
|
|
gptkbp:founder
|
gptkb:Dr._John_M._Mc_Donald
|
|
gptkbp:headquarters
|
gptkb:Austin,_Texas
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Celo Nova Biosciences
|
|
gptkbp:industry
|
gptkb:hospital
|
|
gptkbp:key_people
|
gptkb:Dr._Michael_J._Mc_Carthy
gptkb:Dr._John_M._Mc_Donald
Dr. David A. Heller
|
|
gptkbp:market
|
Global market
|
|
gptkbp:mission
|
To improve patient outcomes through innovative technology.
|
|
gptkbp:partnership
|
Collaborates with various hospitals and clinics
|
|
gptkbp:products
|
gptkb:Celo_Nova_Balloon
gptkb:Celo_Nova_Stent
|
|
gptkbp:regulatory_compliance
|
FDA approved products
|
|
gptkbp:research_and_development
|
Invests heavily in R& D
|
|
gptkbp:specializes_in
|
Cardiovascular Devices
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.celonovabio.com
|
|
gptkbp:bfsParent
|
gptkb:Boston_Scientific
|
|
gptkbp:bfsLayer
|
4
|